What combination therapy with a statin, if any, would you recommend?

Current Atherosclerosis Reports

Volumn 13, Issue 1, 2011, Pages 12-22

  Dujovne, Carlos A ^a,b   Williams, Craig D ^a,c   Ito, Matthew K ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UHN 62   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

Author keywords

Atherosclerotic cardiovascular disease; Atorvastatin; Bile acid binders; Combination therapy guidelines; Combined dyslipidemia; Dyslipidemia; FDA ruling on combination therapy for dyslipidemia; Fibrates; Fish oils; Fluvastatin; High density lipoprotein cholesterol; Hypercholesterolemia; Lovastatin; Low density lipoprotein cholesterol; Mixed dyslipidemia; National cholesterol education guidelines on combination drug therapy for dyslipidemias; Niacins; Omega 3 fatty acids; Pravastatin; Rosuvastatin; Simvastatin; Statin plus other lipid regulating agents; Statins; Triglycerides

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ENDUR ACIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ISPAGULA; LIPOPROTEIN; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OCTADECANOL; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ESTER; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STANOZOLOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOALPHALIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER FUNCTION TEST; MYALGIA; MYOPATHY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRURITUS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, LDL; CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG COSTS; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LONG-TERM CARE; MAXIMUM TOLERATED DOSE; PRACTICE GUIDELINES AS TOPIC; TRIGLYCERIDES;

EID: 79551573506     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0150-3     Document Type: Article

References (47)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
2. JC Fruchart, et al. 2008 The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 1K 34K 10.1016/j.amjcard.2008.10.002 19068318
3. KJ Felix-Getzik EM RH Karas 2010 Nonoptimal high-density lipoprotein cholesterol levles are highly prevalent in patients presenting with actue coronary syndromes and well controlled low density lipoprotein cholesterol levels J Clin Lipid 4 265 271 10.1016/j.jacl.2010.04.001
4. PJ Barter, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 1:CAS:528:DC%2BD2sXhtlGns7bL 10.1056/NEJMoa0706628 17984165 (Pubitemid 350146106)
5. HN Ginsberg, et al. 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563 1574 10.1056/NEJMoa1001282 20228404 This article is a comprehensive review on the subject
6. Standards of medical care in diabetes-2010. Diabetes Care 33 Suppl 1, S11-61 (2010).
7. SC Smith Jr, et al. 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2363 2372 10.1161/CIRCULATIONAHA.106.174516 16702489 (Pubitemid 43947981)
8. I Tabas KJ Williams J Boren 2007 Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 1832 1844 1:CAS:528:DC%2BD2sXhtFersLnL 10.1161/CIRCULATIONAHA. 106.676890 17938300 (Pubitemid 350287108)
9. JL Witztum 1994 The role of oxidized LDL in the atherogenic process J Atheroscler Thromb 1 71 75 1:CAS:528:DyaK28XksVarurk%3D 9222872
10. JE Kanter F Johansson RC LeBoeuf KE Bornfeldt 2007 Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 100 769 781 1:CAS:528:DC%2BD2sXjtlWnu7g%3D 10.1161/01.RES.0000259589.34348.74 17395883 (Pubitemid 46555682)
11. AJ Taylor, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 1:CAS:528:DC%2BD1MXhsFSnsLzP 10.1056/NEJMoa0907569 19915217
12. HE Bays, et al. 2001 Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies Clin Ther 23 1209 1230 1:CAS:528:DC%2BD3MXnt1SntLc%3D 10.1016/S0149-2918(01)80102-8 11558859 (Pubitemid 32804115)
13. E Stein, et al. 2004 Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin Am Heart J 148 447 455 1:CAS:528: DC%2BD2cXnvVOju7g%3D 10.1016/j.ahj.2004.03.052 15389231 (Pubitemid 39265117)
14. J Jurado R Seip PD Thompson 2004 Effectiveness of ezetimibe in clinical practice Am J Cardiol 93 641 643 1:CAS:528:DC%2BD2cXhslWms78%3D 10.1016/j.amjcard.2003.11.040 14996600 (Pubitemid 38293080)
15. AL Catapano, et al. 2006 Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients Curr Med Res Opin 22 2041 2053 1:CAS:528:DC%2BD28Xht1KltrvM 10.1185/030079906X132721 17022864 (Pubitemid 44663409)
16. JJ Kastelein, et al. 2008 Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 1431 1443 1:CAS:528: DC%2BD1cXkt12qt7c%3D 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
17. TJ Smilde, et al. 2001 Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 577 581 1:CAS:528:DC%2BD3MXhsVKltbo%3D 10.1016/S0140-6736(00)04053-8 11558482 (Pubitemid 32179609)
18. PR Nolting, et al. 2003 Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin Arch Intern Med 163 1837 1841 10.1001/archinte.163.15.1837 12912721 (Pubitemid 36960934)
19. JJ Kastelein ML Bots 2009 Statin therapy with ezetimibe or niacin in high-risk patients N Engl J Med 361 2180 2183 1:CAS:528:DC%2BD1MXhsFWgs7rI 10.1056/NEJMe0908841 19915218
20. WJ Howard 2010 The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS Nutr Metab Cardiovasc Dis 20 295 300 1:CAS:528:DC%2BC3cXhtVGlsbrO 10.1016/j.numecd.2010.05.002 20556890 This is a discussion of controversial data regarding ezetimibe safety and efficacy.
21. BV Howard, et al. 2008 Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial JAMA 299 1678 1689 1:CAS:528:DC%2BD1cXks1Wmtbs%3D 10.1001/jama.299.14.1678 18398080 (Pubitemid 351519865)
22. JL Fleg, et al. 2008 Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial J Am Coll Cardiol 52 2198 2205 1:CAS:528:DC%2BD1cXhsFajs7rJ 10.1016/j.jacc.2008.10.031 19095139 This is a clarification on the effects on ezetimibe plus statins on endpoints results
23. RM Califf, et al. 2010 An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 705 709 10.1016/j.ahj.2010.03.004 20435175
24. AB Rossebo, et al. 2008 Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 1343 1356 10.1056/NEJMoa0804602 18765433 This shows the results of a simvastatin/ezetimibe combination study with important endpoints
25. R Peto, et al. 2008 Analyses of cancer data from three ezetimibe trials N Engl J Med 359 1357 1366 1:CAS:528:DC%2BD1cXhtFKjtrrL 10.1056/NEJMsa0806603 18765432
26. PJ Barter KA Rye 2008 Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28 39 46 1:CAS:528:DC%2BD2sXhsVeiu7nJ 10.1161/ATVBAHA.107.148817 17717290
27. A Keech, et al. 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 1849 1861 1:STN:280: DC%2BD2MnjtVCnsg%3D%3D 10.1016/S0140-6736(05)67667-2 16310551 (Pubitemid 41690113)
28. L Cashin-Hemphill, et al. 1990 Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up JAMA 264 3013 3017 1:STN:280:DyaK3M%2Fls1Kmsg%3D%3D 10.1001/jama.264.23.3013 2243429
29. G Brown, et al. 1990 Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1289 1298 1:STN:280:DyaK3M%2FhsFaksw%3D%3D 10.1056/ NEJM199011083231901 2215615
30. DH Blankenhorn, et al. 1987 Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 3233 3240 1:STN:280:DyaL2s3is1GrtQ%3D%3D 10.1001/jama.257.23. 3233 3295315 (Pubitemid 17078320)
31. AJ Taylor, et al. 2004 Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 3512 3517 1:CAS:528:DC%2BD2MXhtVGnt7s%3D 10.1161/01.CIR.0000148955.19792.8D 15537681 (Pubitemid 39612564)
32. BG Brown, et al. 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 1:CAS:528:DC%2BD3MXoslyhsLs%3D 10.1056/NEJMoa011090 11757504 (Pubitemid 33126837)
33. Knopp, R., et al. Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects: Clues to Mechanism of Action of Niacin. Metabolism, 642-50 (1985).
34. CA Dujovne 2002 Side effects of Statins: Hepatitus Versus 'Transaminitis'-Myositis vs 'CPKitis' The American Journal of Cardiology 89 1411 1413 1:CAS:528:DC%2BD38XksVait7o%3D 10.1016/S0002-9149(02)02356-1 12062737 (Pubitemid 34607783)
35. A Stein, et al. 1996 Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial J Cardiovasc Pharmacol Therapeut 1 2 107 116 1:CAS:528:DyaK28XlvFOntLk%3D
36. B Bays, et al. 2003 Comparison of Once-Daily, Niacin Extended-Release/ Lovastatin With Standard Doses of Atorvastatin and Simvastatin (The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation (ADVOCATE)) The American Journal of Cardiology 91 667 672 1:CAS:528:DC%2BD3sXhvFeqtLY%3D 10.1016/S0002-9149(03)00007-9 12633795 (Pubitemid 36287455)
37. CM Ballantyne, et al. 2008 Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study) Am J Cardiol 101 10 1428 36 1:CAS:528:DC%2BD1cXlslyiurs%3D 10.1016/j.amjcard.2008.02.092 18471454 This is an excellent study of statin-niacin combination therapy and efficacy
38. RH Karas, et al. 2008 Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with Dyslipidemia: the OCEANS study Am J Cardiovasc Drugs. 8 2 69 81 1:CAS:528:DC%2BD1cXns1artLs%3D 10.2165/00129784-200808020-00001 18422390 (Pubitemid 351570857)
39. JM McKenney, et al. 1998 A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collabortive Atorvastatin Study Group Am J Med. 104 2 137 43 1:CAS:528:DyaK1cXitFemsb0%3D 10.1016/S0002-9343(97)00311-2 9528731 (Pubitemid 28117407)
40. DM Capuzzi, et al. 2004 Rosuvastatin Alone or With Extended-Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia Preventive Cardiology. 7 4 176 81 1:CAS:528:DC%2BD2MXht12hug%3D%3D 10.1111/j.1520-037X.2004.3217.x 15539964
41. Brown, F., et al. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. N Engl J Med., 1583-92 (2001).
42. WS Harris, et al. 1988 Effects of a Low Saturated Fat, Low Cholesterol Fish Oil Supplement in Hypertriglyceridemic Patients-A Placebo Controlled Trial Ann Intern Med 109 6 464 470
43. MH Davidson, et al. 2007 The COMBination of prescription omega-3 with Simvastatin (COMBOS) investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther. 29 1354 1367 1:CAS:528:DC%2BD2sXhtVemurjN 10.1016/j.clinthera.2007.07.018 17825687 (Pubitemid 47348116)
44. A Nordoy, et al. 1998 Effects of Simvastatin and Omega-3 Fatty Acids on Plasma Lipoproteins and Lipid Peroxidation in Patients with Combined Hyperlipidemia J Int Med 243 163 170 1:CAS:528:DyaK1cXisVWnsLg%3D 10.1046/j.1365-2796.1998.00297.x (Pubitemid 28156665)
45. PN Durrington, et al. 2001 An Omega-3 Polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia Heart 85 5 544 8 1:STN:280:DC%2BD3M3ms1SqtA%3D%3D 10.1136/heart.85.5.544 11303007
46. R Marchioli, et al. 2002 Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione Circulation. 105 16 1897 1903 1:CAS:528:DC%2BD38XktFajtbc%3D 10.1161/01.CIR.0000014682.14181.F2 11997274 (Pubitemid 34437615)
47. The JELIS study M Yokoyama H Origasa 2003 JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS) Am Heart J 146 613 620 1:CAS:528:DC%2BD3sXotVCju78%3D 10.1016/S0002-8703(03)00367-3 14564313 (Pubitemid 37281704)